Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A risk score for in-hospital death in patients admitted with ischemic or hemorrhagic stroke.

Journal of the American Heart Association·2013

Same author

American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers.

Circulation·2013

Same author

Ultrafiltration in heart failure with cardiorenal syndrome.

The New England journal of medicine·2013

Same author

Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.

The American journal of medicine·2013

Same author

Renin-Angiotensin system antagonists and mortality in patients with heart failure.

JAMA·2013

Same author

Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure.

The American journal of medicine·2013

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Comprehensive adrenergic blockade post myocardial infarction left ventricular dysfunction.

Gregg C Fonarow¹

¹Geffen School of Medicine at UCLA, UCLA Medical Center, Los Angeles, CA, USA. gfonarow@mednet.ucla.edu

Cardiology Clinics

|March 4, 2008

Summary

Beta-blocker therapy is recommended for post-myocardial infarction (MI) patients, especially those with left ventricular dysfunction (LVD). Evidence supports their use to reduce cardiovascular events and mortality.

More Related Videos

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

Related Experiment Videos

Last Updated: Jul 7, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

Area of Science:

Cardiology
Pharmacology

Background:

Post-myocardial infarction (MI) patients, particularly those with left ventricular dysfunction (LVD), face elevated risks of adverse cardiovascular outcomes.
Current guidelines strongly recommend indefinite oral beta-blocker therapy for these individuals unless contraindicated.
Suboptimal prescription rates and use of unproven agents persist in this high-risk population.

Purpose of the Study:

To review clinical trial evidence supporting beta-blocker use in post-MI patients with LVD.
To elucidate the rationale for selecting specific beta-blocker agents.
To outline practical strategies for implementing evidence-based beta-blocker therapy in post-MI care.

Main Methods:

Review of pivotal clinical trials and meta-analyses on beta-blocker efficacy in post-MI patients with LVD.
Analysis of pharmacological properties and clinical outcomes associated with different beta-blocker classes.
Discussion of guideline recommendations and clinical practice considerations.

Main Results:

Beta-blockers significantly reduce the risk of recurrent cardiovascular events, heart failure, and mortality in post-MI patients with LVD.
Specific beta-blockers have demonstrated consistent benefits, supported by robust trial data.
Implementation challenges include patient adherence and physician prescribing patterns.

Conclusions:

Evidence strongly supports the use of specific beta-blockers for post-MI patients with LVD.
Optimizing beta-blocker prescription and adherence is crucial for improving long-term outcomes.
Practical approaches are needed to ensure consistent application of evidence-based therapy.